Crossmark

PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation

Crossref DOI link: https://doi.org/10.1186/s12943-017-0684-x

Published Online: 2017-06-28

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tutuka, Candani S. A.

Andrews, Miles C.

Mariadason, John M.

Ioannidis, Paul

Hudson, Christopher

Cebon, Jonathan

Behren, Andreas https://orcid.org/0000-0001-5329-280X
Funding

Funding for this research was provided by:

Cancer Council Victoria (Not applicable)

National Health and Medical Research Council (1055456, 1046092)